

Short Communication

DOI: 10.4274/tjps.galenos.2021.63060

Multi-drug treatment for COVID-19-induced acute respiratory distress syndrome

Masashi Ohe

Department of Internal Medicine, JCHO Hokkaido Hospital, Sapporo, Japan

*Address correspondence to:

Dr. Masashi Ohe

Department of Internal Medicine, JCHO Hokkaido Hospital,
1-8-3-18 Nakanoshima, Toyohira-ku, Sapporo 062-8618, Japan

E-mail: oehtsp1218@sweet.ocn.ne.jp

0000-0002-6684-6688

Tel: +81-11-831-5151

Fax: +81-11-821-3851

19.07.2021

06.09.2021

06.10.2021

Keywords: COVID-19, doxycycline, azithromycin, ivermectin, corticosteroid

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), broke out in late 2019 to become a serious global threat to human health. In the absence of specific treatments for COVID-19, treatment options are being examined. Recently, the anti-SARS-CoV-2 activities of tetracyclines, macrolide antibiotics, and ivermectin, have attracted considerable attention for their potential as single or multi-drug treatment regimen. Moreover, tetracyclines, macrolide antibiotics, and ivermectin possess anti-inflammatory and immunomodulatory effects to reduce the production of cytokines. COVID-19 is characterized by early exponential viral replication, cytokine storm-associated organ damage, including acute respiratory distress syndrome (ARDS) and thrombosis. Considering anti-inflammatory and immunomodulatory effects of the aforementioned drugs and corticosteroids, early treatment with ivermectin, doxycycline, azithromycin, and

corticosteroids is thought to be the most promising option for combating COVID-19-induced ARDS.

INTRODUCTION

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), broke out in late 2019 to become a serious global threat to human health. In the absence of specific treatments for COVID-19, treatment options are being examined. Recently, the anti-SARS-CoV-2 activities of tetracyclines (e.g., doxycycline (DOX)), macrolide antibiotics (e.g., azithromycin (AZM), and clarithromycin (CAM)), and macrolide antiparasitics (e.g., ivermectin (IVM)), have attracted considerable attention for their potential as single or multi-drug treatment regimen.

Apart from anti-SARS-CoV-2 activities, DOX, AZM, and IVM possess anti-inflammatory and immunomodulatory effects to reduce the production of interleukin (IL)-6, IL-8, and tumor necrosis factor (TNF)- α ; IL-1, IL-6, IL-8, and TNF- α ; and IL-1, IL-6, and TNF- α , respectively (1-3).

In single-drug treatment studies in COVID-19, DOX (4), CAM (5), and IVM (6) have proven effective against COVID-19.

In multi-drug treatment studies, Alam et al. (7) found that a combination of IVM and DOX was effective for viral clearance in patients with mild and moderate COVID-19. Prasad (8) reported on a patient where COVID-19 accompanied by pulmonary lesion was successfully treated with the early administration of IVM (6 mg twice daily for 3 days), AZM (500 mg daily for 5 days), DOX (100 mg twice daily for 5 days), and prednisolone (50 mg daily for 5 days) followed by dexamethasone (6 mg daily).

The primary purpose of the aforementioned drug treatments is to improve mild and moderate COVID-19 cases and prevent them from further deteriorating into the severe, life-threatening stage. Severe COVID-19 involves cytokine storm-associated organ damage, including acute respiratory distress syndrome (ARDS). Elevated blood levels of IL-6, IL-8, IL-10, and TNF- α were noted in COVID-19-induced ARDS (9), which was effectively treated with cytokine storm suppression, either using IL-6 inhibitor tocilizumab (TCZ) (10) or a combination of TCZ and IVM (11).

Corticosteroids known to reduce the production of IL-6, IL-8, IL-10, and TNF- α (12), were also found to reduce mortality in the patients with COVID-19-induced-ARDS and non-COVID-19-induced ARDS (13).

Tetracycline treatment within a year prior to ARDS diagnosis was associated with 75%

reduced likelihood for mechanical ventilation during a hospital stay (14). Furthermore, tetracycline treatment corresponded to significant reductions in the length of mechanical ventilation use and intensive care unit stay in patients with ARDS (14). Although this study was performed in patients with non-COVID-19, these results suggest that tetracycline may be effective for COVID-19-induced ARDS. Additionally, treatment with macrolide antibiotics has also been associated with reduced mortality in ARDS (15).

Multi-drug treatment is thought to be more effective than single-drug treatment because of the synergistic effect of the different mechanisms of action of the component drugs (16).

Taken together, from a medical economic standpoint, early treatment with IVM, DOX, AZM, and corticosteroids may be the most promising option for combating COVID-19-induced ARDS.

However, clinical trials need to be conducted to better assess the optimal doses and durations for these medications as well as the efficacy and tolerability of this treatment before it can be implemented on a wider scale.

Conflict of interest

The authors report no potential conflicts of interest relevant to this article.

References

1. Bernardino ALF, Kaushal D, Philipp MT. The antibiotics doxycycline and minocycline inhibit inflammatory responses to the Lyme disease spirochete *Borrelia burgdorferi*. *J Infect Dis*. 2009; 199: 1379-1388. doi: 10.1086/597807.
2. Zimmermann P, Ziesenis VC, Curtis N, Ritz N. Macrolide- A Systemic Review of the Underlying Mechanisms. *Front Immunol*. 13;2018
<https://doi.org/10.3389/fimmu.2018.00302>
3. Zhang X, Song Y, Ci X, An N, Ju Y, Li H, Wang X, Han C, Cui J, Deng X. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. *Inflamm Res*. 2008 Nov;57(11):524-529. doi: 10.1007/s00011-008-8007-8. PMID: 19109745.
4. Gironi LC, Damiani G, Zavattaro E, Pacifico A, Santus P, Pigatto PDM, Cremona O, Savoia P. Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses. *Dermatol Ther*. 2021; 34: e14694. doi:

10.1111/dth.14694.

5. Tsiakos K, Tsakiris A, Tsibris G, Voutsinas P, Panagopoulos P, Kosmidou M, Petrakis V, Gravvani A, Gkavogianni T, Klouras E, Katrini K, Koufargyris P, Rapti I, Karageorgos A, Vrenzos E, Damoulari C, Zarkada V, Sidiropoulou C, Artemi S, Ioannidis A, Papapostolou A, Michelakis E, Georgiopoulou M, Myrodia DM, Tsiamalos P, Syrigos K, Chrysos G, Nitsotolis T, Milionis H, Poulakou G, Giamarellos-Bourboulis E-J. Oral clarithromycin in COVID-19 of moderate severity: The ACHIEVE open label trial using concurrent matched comparators. doi: <https://doi.org/10.1101/2020.12.22.20248753>
6. Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, Rahman M, Zaman K, Somani J, Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. *Int J Infect Dis.* 2021; 103:214-216.
7. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline. *Bangladesh Coll Phys Surg.* 2020; 38:10- 15.
8. Prasad A. Early administration of ivermectin, azithromycin & doxycycline along with i.v. prednisolone in a case of COVID -19 disease may lead to early recovery? *Int J Pharm Chem Anal.* 2020; 7:149-150.
9. Wang J, Yang X, Li Y, Huang J, Jiang J, Su N. Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction. *Virol J.* 2021; 18: 117 doi: 10.1186/s12985-021-01588-y.
10. Menzella F, Fontana M, Salvarani C, Massari M, Ruggiero P, Scelfo C, Barbieri C, Castagnetti C, Catellani C, Gibellini G, Falco F, Ghidoni G, Livrieri F, Montanari G, Casalini E, Piro R, Mancuso P, Ghidorsi L, Facciolo N. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. *Crit Care.* 2020 Sep 29;24(1):589. doi: 10.1186/s13054-020-03306-6. PMID: 32993751; PMCID: PMC7523258.
11. Chuang TY, Tsai MH, Wu LM, Ho SJ, Yeh PS, Liu YL, Yang HJF. Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19. *J Microbiol Immunol Infect.* 2021;54(1):147-148. doi:10.1016/j.jmii.2020.09.007
12. Giamarellos-Bourboulis EJ, Dimopoulou I, Kotanidou A, Livaditi O, Pelekanou A, Tsagarakis S, Armaganidis A, Orfamos SE. Ex-vivo effect of dexamethasone on

cytokine production from whole blood of septic patients: correlation with disease severity. *Cytokine*, 2010;49:89–94.

13. Chaudhuri D, Sasaki K, Karkar A, Sharif S, Lewis K, Mammen MJ, Alexander P, Ye Z, Lozano LEC, Munch MW, Perner A, Du B, Mbuagbaw L, Alhazzani W, Pastores SM, Marshall J, Lamontagne F, Annane D, Meduri GU, Rochwerf B. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. *Intensive Care Med* 2021; **47**:521–537.

<https://doi.org/10.1007/s00134-021-06394-2>

14. Byrne JD, Shakur R, Collins JE, Becker S, Young CC, Boyce H, Traverso G. Prophylaxis with tetracyclines in ARDS: Potential therapy for COVID-19-induced ARDS? medRxiv preprint doi: [10.1101/2020.07.22.20154542](https://doi.org/10.1101/2020.07.22.20154542).

15. Simonis FD, de Iudibus G, Cremer OL, Ong DSY, van der Poll T, Bos LD, Schultz MJ. Macrolide therapy is associated with reduced mortality in acute respiratory distress syndrome (ARDS) patients. *Ann Transl Med* 2018; 6(2): 24. doi:

<https://doi.org/10.21037/atm.2017.12.25>

16. Ohe M, Furuya K, Goudarzi H. Multidrug treatment for COVID-19. *Drug Discov Thera* 2021;15:39-41.